Summary
Global Markets Direct’s, ‘Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ligand Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc.
- The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ligand Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ligand Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Ligand Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Ligand Pharmaceuticals, Inc. Snapshot 6
Ligand Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Ligand Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Ligand Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Ligand Pharmaceuticals, Inc. - Pipeline Products Glance 19
Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Ligand Pharmaceuticals, Inc. - Drug Profiles 24
lasofoxifene tartrate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
clopidogrel bisulfate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
aplindore fumarate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
pradefovir mesylate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MB-07133 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LGD-6972 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug to Inhibit JAK3 for Inflammation 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LG-7455 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LGD-3437 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LGD-7501 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PS-031291 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Antagonize CCR1 for Oncology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Activate Glucokinase for Type 2 Diabetes 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Ligand Pharmaceuticals, Inc. - Pipeline Analysis 40
Ligand Pharmaceuticals, Inc. - Pipeline Products by Target 40
Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 42
Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 43
Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 44
Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates 46
Ligand Pharmaceuticals, Inc. - Dormant Projects 51
Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
adipiplon 52
clopidogrel bisulfate 52
LGD-5552 52
managlinat dialanetil 52
NGD-2000-1 53
NGD-91-1 53
NGD-91-2 53
NGD-91-3 53
NGD-94-1 53
NGD-94-4 53
NGD-96-1 53
NGD-97-1 53
Vanilloid Receptor-1 Program 54
Ligand Pharmaceuticals, Inc. - Company Statement 55
Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59
List of Tables
Ligand Pharmaceuticals, Inc., Key Information 6
Ligand Pharmaceuticals, Inc., Key Facts 6
Ligand Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8
Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12
Ligand Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 16
Ligand Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17
Ligand Pharmaceuticals, Inc. - Pre-Registration, 2016 19
Ligand Pharmaceuticals, Inc. - Phase III, 2016 20
Ligand Pharmaceuticals, Inc. - Phase II, 2016 21
Ligand Pharmaceuticals, Inc. - Phase I, 2016 22
Ligand Pharmaceuticals, Inc. - Preclinical, 2016 23
Ligand Pharmaceuticals, Inc. - Pipeline by Target, 2016 40
Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 42
Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 43
Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 44
Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 46
Ligand Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 51
Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 52
Ligand Pharmaceuticals, Inc., Subsidiaries 56
List of Figures
Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 8
Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12
Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 16
Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 40
Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 42
Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 43
Ligand Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 44
